Chemours (NYSE: CC) reported Q4 EPS of $0.61, $0.20 better than the analyst estimate of $0.41. Revenue for the quarter came in at $1.3 billion versus the consensus estimate of $1.28 billion.

GUIDANCE:

Chemours sees FY2021 EPS of $2.40-$3.12, versus the consensus of $2.60.

For earnings history and earnings-related data on Chemours (CC) click here.